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Population based germline testing for primary cancer prevention 
Next generation sequencing technologies [1, 2], increasing affordability, the ability to undertake high 
throughput large volume testing and advances in bioinformatics has made large scale population 
based genetic testing technically feasible. Coupled with a rapidly changing genomic landscape, 
improved genetic understanding of disease and increasing awareness, this offers a massive 
opportunity to apply this knowledge and technology on a broad population scale to make an 
important shift in healthcare towards disease prevention. Primary prevention and early detection 
strategies remain the cornerstone for reducing the burden of cancers in the population and this 
underpins the clinical utility of genetic testing for moderate/high penetrance cancer gene mutations. 
The traditional approach to genetic-testing is based on an a priori threshold of mutation prevalence 
which is calculated using clinical-criteria centred mainly on family-history (FH). For BRCA-mutations 
this used to be set at 20% probability, which was subsequently reduced to around 10% probability. 
Approaches in use in clinical practice for this purpose range from assessing the FH through number 
of standardised clinical criteria to complex prediction models. This clinical-criteria/FH-based 
approach has a number of limitations. It needs family members to be aware of the FH of cancer, and 
both members of the family and the GP/health professional consulted to understand the importance 
of this history and then make the referral to a genetics centre. We and others have shown this gate 
keeper approach misses over half the mutation carriers at risk. Small families, poor communication, 
paternal inheritance, limited awareness, etc. contribute to the poor performance of criteria based 
testing in ruling out the presence of a mutation. The current system is associated with huge 
underutilisation of genetic testing and delayed identification of unaffected individuals.[3, 4] Over 
80% of eligible patients using National Cancer Comprehensive Network criteria in the USA have not 
been referred/undergone testing. We recently estimated that only 3% of the estimated BRCA-
carriers across Greater London (16-million population) had been identified and using forecasting 
models showed the current rates of testing are inadequate to detect all BRCA-carriers in the 
population.[4] A number of these limitations can be overcome by removing restrictions, broadening 
access and offering testing to everyone, i.e. population-testing.  
Population based BRCA-testing in the Jewish population has been thoroughly investigated in the UK 
Genetic Cancer Prediction through Population Screening (GCaPPS) randomised-controlled trial (RCT) 
(ISRCTN73338115),[5] as well as in Israeli[6] and Canadian[7] single-arm cohort studies. Data show 
that in the Jewish-population unselected BRCA-testing identifies >50% additional BRCA-carriers, is 
acceptable, feasible, can be undertaken in a community setting and does not adversely affect 
psychological well-being or quality-of-life compared to FH-based testing, and has high satisfaction 
rates.[5, 8] Additionally such an approach is highly cost-effective for both UK and US health 
systems.[9-11]  In fact it is cost-saving in most scenarios. There is thus strong evidence to support 
change in paradigm to population-based BRCA-testing in the Jewish community. However, these 
data cannot be directly extrapolated to the non-Jewish general population.  
Nevertheless, general (non-Jewish) population testing offers the opportunity to use genomics to 
maximise cancer prevention/early detection and reduce cancer burden on a much larger scale. Why 
should individuals in the family need to develop cancer before other unaffected individuals in the 
family can be identified? Additionally, the availability of panel germline testing now enables 
population testing to be undertaken for multiple cancer susceptibility genes but the genes included 
must have ‘well-established’ clinical-utility. Surgical prevention is cost-effective[12, 13] for the 
newer moderate penetrance OC gene mutations RAD51C/RAD51D/BRIP1 (OC lifetime risks ~6-11%) 
and testing for these is now established in clinical practice.[14] PALB2 is a moderate-risk gene with 
BC-risks[15] for which MRI/mammogram screening and risk-reducing mastectomy is available. In 
addition the Lynch Syndrome associated genes MLH1, MSH2 and MSH6 are also potential candidates 
that could become part of an extended population germline testing panel.  
We recently modelled population testing for multiple BC and OC gene mutations 
(BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2) compared to the traditional clinical-criteria/FH-
based approach.[16] We showed that panel testing for multiple OC/BC genes was more cost-
effective than BRCA-testing alone. Critically, population based testing for 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 was more cost-effective than any currently used 
clinical-criteria/family-history based strategy. The ICER (incremental cost-effectiveness ratio) was 
£21,599.96/QALY and $54,769.78/QALY for UK and US health systems, well below the thresholds of 
£30,000/QALY and $100,000/QALY in the UK and USA respectively. This amounts to 9.34 or 7.57 
days life-expectancy gained (across the population). Robust sensitivity analyses (10,000 simulations 
on probabilistic sensitivity analysis) indicated that population testing is cost-effective and the 
preferred strategy in 84% simulations in the UK and 93% simulations in the USA models respectively. 
Such an approach could potentially prevent an additional 657/655 OC-cases and 2420/2386 BC cases 
per million UK/USA women respectively. Extrapolating this across the population amounts to 
potentially 17505 and 65221 OC cases prevented in UK and USA women and 64493 and 237610 BC 
cases prevented in UK and USA women respectively. However, cost-effectiveness analysis, incurs 
assumptions, and further research is necessary to prospectively validate some key assumptions, such 
as, the surgical prevention uptake rates in those without a strong FH of cancer. 
The feasibility of population based germline panel testing for OC gene mutations has been 
demonstrated in an ongoing pilot study in London.[17] The time has come to undertake large 
research studies to evaluate the impact of population based panel germline testing in an unselected 
non-Jewish general population. This includes impact on quality-of-life, psychological well-being, 
satisfaction and long-term health-behaviour and lifestyle. The best implementation model to deliver 
this approach also needs to be identified through robust evaluation and comparison with the current 
standard of care in well-designed trial(s). A key issue which will need resolving is a system for 
ongoing monitoring, reclassification (where needed) and management of VUS (variants of uncertain 
significance). Other matters that need tackling include increasing public/health professional 
awareness and education, delivery logistics, quality-control, call-recall mechanisms and expansion of 
downstream pathways of care. These steps are necessary for the health-system to achieve its 
maximum potential for reducing burden of disease now afforded through cancer screening and 
prevention. 
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